Interferon-β treatment associated with a biochemical profile suggestive of acromegaly. A case report of a patient treated for multiple sclerosis

被引：4
作者：
Andreassen, Mikkel [1 ]
Frystyk, Jan [2 ,3 ]
Miller, Karen K. [4 ]
Kristensen, Lars O. [1 ]
机构：
[1] Univ Copenhagen, Herlev Hosp, Endocrine Unit, Dept Internal Med O,Lab Endocrinol, DK-2730 Herlev, Denmark
[2] Aarhus Univ Hosp, Med Res Labs, Inst Clin, DK-8000 Aarhus C, Denmark
[3] Aarhus Univ Hosp, Med Dept M, DK-8000 Aarhus C, Denmark
[4] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neuroendocrine Unit,Dept Med, Boston, MA 02115 USA
来源：
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION | 2010年 / 70卷 / 07期
关键词：
Multiple sclerosis; interferon-beta treatment; growth hormone; insulin-like growth factor-I; insulin-like growth factor I receptor; GROWTH-FACTOR-I; DISEASE; SERUM;
D O I：
10.3109/00365513.2010.521256
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
We describe a 34-year-old female treated with IFN-beta for 8 years with a biochemical profile suggestive of acromegaly. The patient presented with elevated serum insulin-like growth factor-I (IGF-I) and insufficient suppression of growth hormone (GH) during oral glucose tolerance test (OGTT). There were no clinical features of acromegaly. A 5-day profile showed higher GH levels on the 3 days following IFN-beta injections. Total and bioactive IGF-I were also elevated but did not fluctuate. Four weeks off IFN-beta normalized suppression of GH during OGTT but did not reduce serum IGF-I or bioactive IGF-I. In conclusion, IFN-beta treatment mimicked acromegaly biochemically. The changes were partially reversible.
引用
收藏
页码：519 / 522
页数：4
相关论文
共 15 条
  • [1] Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-β 1a or 1b therapy:: Predictive factors of thyroid disease development and duration
    Caraccio, N
    Dardano, A
    Manfredonia, F
    Manca, L
    Pasquali, L
    Iudice, A
    Murri, L
    Ferrannini, E
    Monzani, F
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (07) : 4133 - 4137
  • [2] A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum
    Chen, JW
    Ledet, T
    Orskov, H
    Jessen, N
    Lund, S
    Whittaker, J
    De Meyts, P
    Larsen, MB
    Christiansen, JS
    Frystyk, J
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2003, 284 (06): : E1149 - E1155
  • [3] DEL MP, 1995, HORM RES, V44, P105
  • [4] Basal and glucose-suppressed GH levels less than 1 μg/L in newly diagnosed acromegaly
    Pamela U. Freda
    Carlos M. Reyes
    Abu T. Nuruzzaman
    Robert E. Sundeen
    Jeffrey N. Bruce
    [J]. Pituitary, 2003, 6 (4) : 175 - 180
  • [5] Frystyk J, 1995, GROWTH REGULAT, V5, P169
  • [6] Bioactive Insulin-Like Growth Factor-I in Obesity
    Frystyk, J.
    Brick, D. J.
    Gerweck, A. V.
    Utz, A. L.
    Miller, K. K.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (08) : 3093 - 3097
  • [7] The current status of IGF-I assays - A 2009 update
    Frystyk, Jan
    Freda, Pamela
    Clemmons, David R.
    [J]. GROWTH HORMONE & IGF RESEARCH, 2010, 20 (01) : 8 - 18
  • [8] Peripartum maternal and foetal ghrelin, growth hormones, IGFs and insulin interrelations
    Fuglsang, J
    Sandager, P
    Moller, N
    Fisker, S
    Frystyk, J
    Ovesen, P
    [J]. CLINICAL ENDOCRINOLOGY, 2006, 64 (05) : 502 - 509
  • [9] A Consensus on Criteria for Cure of Acromegaly
    Giustina, A.
    Chanson, P.
    Bronstein, M. D.
    Klibanski, A.
    Lamberts, S.
    Casanueva, F. F.
    Trainer, P.
    Ghigo, E.
    Ho, K.
    Melmed, S.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (07) : 3141 - 3148
  • [10] Acute interferon β-1b administration alters hypothalamic-pituitary-adrenal axis activity, plasma cytokines and leukocyte distribution in healthy subjects
    Goebel, MU
    Baase, J
    Pithan, V
    Exton, MS
    Saller, B
    Schedlowski, M
    Limmroth, V
    [J]. PSYCHONEUROENDOCRINOLOGY, 2002, 27 (08) : 881 - 892
12